Geistlich Biomaterials - North America Revenue and Competitors
Estimated Revenue & Valuation
- Geistlich Biomaterials - North America's estimated annual revenue is currently $14.8M per year.
- Geistlich Biomaterials - North America's estimated revenue per employee is $251,000
Employee Data
- Geistlich Biomaterials - North America has 59 Employees.
- Geistlich Biomaterials - North America grew their employee count by 9% last year.
Geistlich Biomaterials - North America's People
Name | Title | Email/Phone |
---|
Geistlich Biomaterials - North America Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $7.8M | 31 | 11% | N/A | N/A |
#2 | $12.3M | 49 | -4% | N/A | N/A |
#3 | $15.1M | 60 | 7% | N/A | N/A |
#4 | $8.8M | 35 | -8% | N/A | N/A |
#5 | $3M | 12 | 9% | N/A | N/A |
#6 | $300.4M | 1197 | 3% | N/A | N/A |
#7 | $311.7M | 1242 | 2% | N/A | N/A |
#8 | $0.3M | 1 | -96% | N/A | N/A |
#9 | $8.3M | 33 | 3% | N/A | N/A |
#10 | $13.6M | 54 | 8% | N/A | N/A |
What Is Geistlich Biomaterials - North America?
Geistlich Pharma North America, Inc., is an affiliate of Geistlich Pharma AG who produce and distribute medical devices and pharmaceuticals for regenerative medicine in Wolhusen and Root, Switzerland. The Swiss company forms part of the Geistlich group which has been in family hands since 1851. Geistlich Pharma and its 3 business units Geistlich Biomaterials, Geistlich Surgery, Geistlich Medical have 10 subsidiaries and global distribution, over 500 employees worldwide and is a world leader in regenerative dentistry through its business unit Geistlich Biomaterials. Geistlich Biomaterials continues to lead oral regeneration based upon our history of quality, scientific collaboration and manufacturing excellence. Every Geistlich biomaterial is intentionally designed for a specific application and carefully engineered to preserve its natural structures. Today, our full product portfolio of Bone Substitutes, Membranes and Matrices increase clinical flexibility and expands treatment options in a variety of therapeutic areas. Geistlich Bio-Oss®: Derived from bovine bone and preserved through a unique, patented process which makes it highly similar to human bone. Through its unique properties and reliable clinical outcomes, Geistlich Bio-Oss® remains the essential choice among an expanding range of therapeutic areas. Geistlich Bio-Gide®: A unique bilayer collagen membrane designed to ensure optimal regenerative healing of bone and soft-tissue. It provides excellent wound stability and graft containment with optimal protection for bone regeneration. Geistlich Mucograft®: A collagen matrix designed for gain of keratinized tissue and recession coverage where open healing is required. Geistlich Fibro-Gide®: The first volume-stable collagen matrix designed for soft-tissue augmentation around natural teeth and implants, as a submerged scaffold where an increase in soft-tissue thickness is clinically desired.
keywords:N/AN/A
Total Funding
59
Number of Employees
$14.8M
Revenue (est)
9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 59 | 26% | N/A |
#2 | N/A | 59 | 48% | N/A |
#3 | $3.5M | 60 | 2% | N/A |
#4 | $7.8M | 60 | -5% | N/A |
#5 | $7.8M | 60 | N/A | N/A |